Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

SoliMix – Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes:

Suliqua® (insulin glargine 100 units/mL and lixisenatide) as a favourable alternative to premixed insulin

Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.

This promotional webinar was initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast.
Editorial support for this webinar was provided by OmniaMed Communications.

Next event starting shortly. Already registered?

Interactive webinar
taking place on

Tuesday 2 November 2021
13:00 and 19:00

For adults with suboptimally controlled basal insulin-treated type 2 diabetes, there are a number of possible treatment intensification options available. These include addition of a rapid-acting insulin to the basal insulin regimen, multiple doses of premixed insulin or the addition of a glucagon-like peptide-1 (GLP-1) receptor agonist to basal insulin.1 A fixed-ratio combination of a basal insulin and GLP-1 receptor agonist may also be a convenient option, offering a once-daily injection without the need for increased blood glucose monitoring.2

Join us for a live webinar on Tuesday 2 November at 13.00 and 19.00 hosted by Rory McCrimmon, Dean of Medicine, Professor of Experimental Diabetes and Metabolism and Honorary Consultant, Tayside, Scotland and Ed Jude, Consultant in Diabetes and Endocrinology, Tameside Hospital NHS Foundation Trust. Together they will present and discuss recent results from the SoliMix randomised controlled trial, the first study to directly compare the fixed-ratio combination Suliqua, with a premixed insulin. Throughout the webinar you will have the opportunity to submit your questions for a live question and answer session immediately after the broadcast.

References
1. Davies MJ et al. Diabetes Care 2018;41:2669–701
2. McCrimmon RJ et al. Diabetes Obes Metab 2021;23:1221–31

What does this programme offer?

Live Q&A session with Ed Jude and Rory McCrimmon ready to answer your burning questions
On-demand resources – access education at times that work for you
Register for free today and gain access to this event

Join us for our upcoming webinar

The webinar will be broadcast on Tuesday 2 November 2021
at 13.00 and 19.00

Agenda

5 minutes

Introduction and welcome

  • Setting the scene:
    • The current state of the nation and the reality facing people with uncontrolled type 2 diabetes
    • NICE recommendations for people with uncontrolled type 2 diabetes with an HbA1c  ≥75 mmol/mol [9%] currently on OADs
  • The rationale for using the fixed ratio combination Suliqua (insulin glargine 100 units/mL and lixisenatide)

Rory McCrimmon

20 minutes

Managing diabetes with injectable therapy: Challenging the existing paradigm and the rationale for fixed-ratio combinations

Rory McCrimmon

20 minutes

Advancing basal insulin therapy in the SoliMix trial: Comparing Suliqua to premixed insulin

Rory McCrimmon

15 minutes

Live Q&A session

Ed Jude and
Rory McCrimmon

Rory McCrimmon

Dean of Medicine, Professor of Experimental Diabetes and Metabolism and Honorary Consultant, Tayside, Scotland

Ed Jude

Consultant in Diabetes and Endocrinology, Tameside Hospital NHS Foundation Trust

Resources

You can access video resources, case studies and print materials about the practical use of Suliqua®▼ (insulin glargine
100 units/mL and lixisenatide) for the treatment of type 2 diabetes in adults.
Prescribing information for Suliqua® (insulin glargine 100 units/mL and lixisenatide) can be found here
This promotional webinar has been initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and speakers prior to broadcast. Editorial support for this webinar has been provided by OmniaMed Communications.
© 2021 Sanofi.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Sanofi Tel: 0800 090 2314.Alternatively, send via email to UK-drugsafety@sanofi.com
MAT-GB-2103798 (v1.0) | Date of preparation: September 2021

You are leaving this site.

You are now leaving https://live.diabetesonthenet.com/solimix-advancing-therapy-in-suboptimally-controlled-basal-insulin-treated-type-2-diabetes-suliqua-as-a-favourable-alternative-to-premixed-insulin/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Sanofi.
Sanofi accepts no responsibility for the content or services of the linked site.

This website is for healthcare professionals

This website is for UK and ROI healthcare professionals only. To continue, please confirm that you are a UK or ROI healthcare professional by clicking the ‘Confirm’ button below.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.